ArticlePituitary2025
Urinary incontinence as a novel and underrecognized clinical manifestation of prolactinoma in women.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProlactin exerts numerous pleiotropic effects on various tissues, including smooth muscle. Urinary incontinence, particularly the urge subtype, is primarily associated with detrusor overactivity-the involuntary contractions of the bladder's smooth muscle. The aim of this study is to investigate the potential impact of prolactinoma on urinary incontinence (UI) in women.
methodsThis cross-sectional study included 64 patients with prolactinoma and 80 controls. UI was assessed using the International Consultation on Incontinence Questionnaire-Short Form. Based on this instrument, incontinence was categorized into three subtypes: urge urinary incontinence (UUI), stress urinary incontinence (SUI), and mixed urinary incontinence (MUI).
resultsThe overall rate of UI was significantly higher in prolactinoma patients, with 20 cases (31.3%), compared to 6 cases (7.5%) in the control group (p < 0.001). Compared to the control group, prolactinoma patients exhibited higher rates of UUI and MUI, while no difference was found in SUI rates (p = 0.012, p = 0.008, and p = 0.839; respectively). Incontinent patients had a higher mean age, a greater frequency of macroadenoma, and a longer disease duration compared to continent patients (p = 0.015, p = 0.038, and p < 0.001; respectively). The logistic regression analysis suggested that the disease duration was the only independent predictor of UI in the prolactinoma patients.
conclusionProlactinoma, particularly in the later stages of the disease, may influence detrusor muscle activity in female patients and contribute to an increased prevalence of UI.
Indexed as
Identifiers
40884590What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.